Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-10, Stock:ABBV, The news for the past five days is as follows:
2018-04-03: NEWS1: Tuesday Sector Laggards: Utilities, Healthcare.NEWS2: Tuesday Sector Laggards: Utilities, Healthcare.NEWS3: Johnson & Johnson Stock on March 29, 2018.NEWS4: Aeglea Initiates Lung Cancer Combination Study With Keytruda.NEWS5: Aeglea Initiates Lung Cancer Combination Study With Keytruda.NEWS6: 2 Big Biotech Bargains You Can Buy Now.NEWS7: 2 Big Biotech Bargains You Can Buy Now.NEWS8: Analysts’ Recommendations for Eli Lilly in March 2018.NEWS9: Analysts’ Recommendations for Eli Lilly in March 2018.NEWS10: 2 Big Biotech Bargains You Can Buy Now.NEWS11: Will These Drugs Reach Blockbuster Status?.NEWS12: Will These Drugs Reach Blockbuster Status?.
2018-04-04: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Johnson & Johnson’s Valuation in March 2018.NEWS3: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..NEWS4: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..NEWS5: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS6: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS7: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS8: [$$] Investors smart at ailing pharma deals.NEWS9: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..
2018-04-05: NEWS1: After Hours Most Active for Apr 5, 2018 :  CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE.NEWS2: After Hours Most Active for Apr 5, 2018 :  CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE.NEWS3: MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green.NEWS4: AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars.NEWS5: Tracking the traders' Q1 moves.NEWS6: AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023.NEWS7: AbbVie Deal Allows Biogen To Launch Humira Copy In Europe.NEWS8: AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023.NEWS9: AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis.NEWS10: Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization.NEWS11: Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization.
2018-04-06: NEWS1: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS2: A Look at Enanta Pharmaceuticals’ Financial Performance.NEWS3: Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April.NEWS4: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS5: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS6: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS7: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS8: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS9: AbbVie to Host First-Quarter 2018 Earnings Conference Call.NEWS10: Cancer killer: Tampa’s ‘best-kept secret’ M2Gen collects data from labs and bedsides to help target treatments.NEWS11: [$$] Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira.
2018-04-09: NEWS1: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS2: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS3: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis.NEWS4: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.NEWS5: [$$] Merck eyes best day since 2016, gains help fuel pharma rally.

Answer: Rise